J&J’s Sedasys Sedation System Now “Approvable,” Though Some Questions Remain
This article was originally published in The Pink Sheet Daily
Executive Summary
Outstanding FDA questions pertain to follow-up data, user training and “post-market observance and those sorts of things,” CFO Dominic Caruso told investors during the firm’s first-quarter earnings call April 17.
You may also be interested in...
Biomet Offers $280 Mil. For J&J’s DePuy Trauma Biz; Bid Facilitates Synthes Deal
J&J expects the divestiture to reduce regulatory barriers to its pending $21 billion Synthes acquisition.
J&J Eyes Restructured Device Biz As New CEO Gorsky Steps In
Big changes are underway at J&J. In April, Alex Gorsky will become the company’s new CEO. And the firm plans a restructuring of its device business upon completion of its $20 billion-plus Synthes acquisition in the first half of the year.
J&J Doubles Down On Orthopedics With Synthes Deal; Takes Lead In Trauma
Johnson & Johnson will control a majority of the orthopedic trauma device market and double its stake in the spinal device field by acquiring Synthes for $21.3 billion under a definitive agreement announced April 27.